Boardroom Alpha
Start trial
10-K primary document
BMRN · Annual Report (Form 10-K) · Filed February 26, 2026

Biomarin Pharmaceutical Inc — 10-K exhibit

bmrn-2025xexx1018.htm
Biomarin Pharmaceutical Inc on Boardroom Alpha
Document
Exhibit 10.18

BioMarin Pharmaceutical Inc.
Summary of Independent Director Compensation
The summary below sets forth the compensation received by independent directors serving on the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”). This summary is consistent with what was reported in the Company’s proxy statement previously filed with the Securities and Exchange Commission on April 8, 2025. All independent directors are entitled to receive a combination of annual cash retainers and restricted stock unit (“RSU”) grants as summarized below as compensation for their service on the Company’s Board and Board committees.
Cash Compensation
The following table is a summary of the annual cash compensation payable to the independent directors. Each applicable line item is an additional element of compensation.
Director Position
Annual Cash Compensation
Compensation to All Independent Directors
    
All Independent Directors
$    65,000    
Elements of Compensation in Addition to Director Membership Retainer

Independent Chair of the Board (if applicable)
$    80,000    
Lead Independent Director (if applicable)
$    65,000    
Audit Committee Member
$    13,500    
Audit Committee Chair (premium in addition to committee membership retainer)
$    13,000    
Compensation Committee Member
$    12,000    
Compensation Committee Chair (premium in addition to committee membership retainer)
$    12,000    
Corporate Governance and Nominating Committee Member
$    10,000    
Corporate Governance and Nominating Committee Chair (premium in addition to committee membership retainer)
$    10,000    
Science and Technology Committee Member
$    10,000    
Science and Technology Committee Chair (premium in addition to committee membership retainer)
$    10,000    
Strategy and Transactions Committee Member
$    13,500    
Strategy and Transactions Committee Chair (premium in addition to committee membership retainer)
$    13,000    

Equity Compensation
Annual Award

On the date of our annual meeting of stockholders for a given year, each re-elected independent director receives a RSU grant valued at $400,000, based on the Black-Scholes model valuation using a 30-day trailing average closing price of the Company’s common stock. The shares of common stock subject to the RSUs vest in full on the date immediately prior to the date of the Company’s next regular annual meeting of stockholders (approximately on the one-year anniversary of the grant date), subject to each respective director providing services to the Company through the vesting date.

New Independent Directors

Upon election or appointment, a new independent director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new director will serve prior to the Company’s next annual meeting of stockholders.


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer